Global pharmaceutical executive with extensive experience in R&D, market access, pricing strategy, evidence generation, Business Development and New Product Planning. Proven track record of launching 20+ innovative medicines and indications since 2018, driving double-digit growth and shaping reimbursement strategies for high-value assets in Rare Disease, Oncology, Neuroscience, and Vaccines. Adept at influencing policy, leading cross-functional teams, and implementing transformational operating models leveraging digital tools and AI. Recognized for strategic vision, operational excellence, and ability to deliver sustainable business outcomes.